Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 10/20 | 0.57 |
| ▸ | NPC1 | O15118 | 9/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MLYCD | O95822 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628943 | 0.91 | NPC1 (0.68) | RAB9ANPC1SMN1; SMN2MLYCDL3MBTL1 | |
| SCHEMBL4628549 | 0.84 | HDAC6 (0.57) | HDAC2HDAC8HDAC6RAB9AHDAC1 | |
| SCHEMBL2118595 | 0.83 | HDAC2 (0.69) | HDAC2HDAC8HDAC6RAB9ANPC1 | |
| SCHEMBL751214 | 0.80 | HDAC2 (0.80) | HDAC2HDAC8HDAC6RAB9ANPC1 | |
| SCHEMBL4629046 | 0.80 | CA1 (0.49) | L3MBTL1 | |
| SCHEMBL4626846 | 0.79 | RAB9A (0.55) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2956135 | 0.79 | HPGD (0.47) | HDAC6HDAC4SMN1; SMN2HSD17B10 | |
| Hydrochloric Acid SCHEMBL28193721 | 0.79 | HDAC2 (0.77) | HDAC2HDAC8HDAC6RAB9ANPC1 | |
| SCHEMBL4627897 | 0.78 | L3MBTL1 (0.49) | SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL4628882 | 0.77 | MAPK1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601656-A4 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | claimed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | claimed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | claimed |
| EP-1601656-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | claimed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | claimed |
| EP-1601656-A4 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7138412-B2 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1601656-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-25 | — | — | US | disclosed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
| WO-2004080971-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | HDAC2 294/4885HDAC8 1525/4885HDAC6 2085/4885 |
| US-20040235847-A1 | Tetrahydroquinoline derivatives useful as serine protease inhibitors | TFPI, F2, TFPI2 | HDAC2 1073/4885HDAC8 2772/4885HDAC6 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.